What EBITDA multiple will my medspa sell for?

Medspa multiples range from 3–5x EBITDA for solo/two-provider practices ($500K–$1M EBITDA), 6–10x for established multi-location practices ($2M–$5M EBITDA), and 10–15x+ for larger platforms ($5M+ EBITDA). The highest multiples—15–20x—go to practices with 40%+ net margins, 50%+ recurring revenue, and proven management teams. Your specific multiple depends on growth rate, margin stability, provider dependency, and revenue predictability.

How much does recurring revenue boost a medspa's valuation?

Practices with 50%+ recurring revenue (memberships, loyalty programs, package prepayment) typically see a 1–2x multiple boost compared to those reliant on new-patient acquisition. Recurring revenue is valued higher because it's more predictable and reduces buyer risk of patient churn after acquisition.

How much does owner-injector dependency hurt my medspa's valuation?

If you're the only revenue driver, buyers typically apply a 20–30% valuation haircut because they assume significant patient loss during transition. Practices with multiple trained providers, nurse injectors, and patient loyalty to the brand (not the person) command substantially higher multiples.

What is medspa EBITDA recast and how does it affect my sale price?

Buyers recalculate your EBITDA by adding back owner salary, one-time costs, and non-recurring expenses, then subtracting normalized costs for a replacement owner. If you've been paying yourself $300K when a hired injector costs $150K, they'll normalize that downward, reducing your valuation. Conversely, inflated discretionary spending or inefficient operations can actually increase recasted EBITDA.

Does location and payer mix affect medspa valuation?

Yes—urban, affluent markets with strong toxin/filler demand and low insurance dependency command higher multiples than rural or price-sensitive markets. Geography and payer mix are factored into buyer risk assessment and directly influence the multiple applied to your EBITDA.

What operational factors increase a medspa's EBITDA multiple?

Documented protocols, staff retention, vendor relationships, and marketing efficiency all reduce buyer risk and justify higher multiples. Combined with consistent 35–40% EBITDA margins, year-over-year growth of 15–20%, and multiple revenue-generating providers, these systems signal a scalable, lower-risk acquisition.

Monday, August 24, 2026 Never miss a recall or a rule change Go Pro · $20/mo →

RegulatoryAbbVie Launches Phase 2 Forehead Lines Studytoday MarketFacial Rejuvenation Market Forecast to Hit $5.66B by 20302 days ago Business & M&AAllergan Aesthetics Overhauls Loyalty Programtoday Devices & TechXERF Technology Enters Australian Market for Skin Tightening2 days ago Business & M&AEvolus Expands Estyme to Canada, Australia, New Zealandtoday MarketArm Fat Now Top Body Sculpting Concern in Singapore2 days ago Devices & TechSofwave Hits One Million Treatments Milestonetoday RegulatoryCKD Bio Pursues China Botox Approval—2027 Launch Targeted2 days ago RegulatoryRevance Wins FDA Nod for Under-Eye Injectablesyesterday MarketGLP-1 Pill Era Is Forcing Beauty Market Shiftyesterday InjectablesAEON Releases Expanded ABP-450 Botox Biosimilar Datayesterday Devices & TechUltherapy PRIME Real-Time Imaging Reshapes Midface Liftingyesterday

Reference Guide

What Is Your Medspa Worth? Valuation & EBITDA Multiples

How medspas are valued by buyers, the EBITDA multiples that drive price, what moves the needle on your multiple, and how to read an offer before you call an advisor.

By Evan at Inside MedSpa · Updated Jul 28, 2026

A medspa valuation is not a guess—it's a formula. Buyers (roll-ups, PE firms, strategic acquirers) apply a multiple to your EBITDA, and that multiple depends on size, growth, margin profile, and revenue stickiness. Understanding the mechanics before you talk to anyone positions you to negotiate from fact, not hope. This page walks you through how the market prices medspas, what actually drives multiples up, the deal structures you'll encounter, and the red flags in an offer.

Inside MedSpa Pro

You've reached your free articles this week.

Keep reading every article, unlock the full trackers, and get the twice-a-week intelligence brief — from $20/mo, or $200/yr (two months free). Never miss a recall or a rule change.

Every article, unlocked — no weekly limit
The full 50-state law tracker, stock & M&A watch
The twice-a-week, 2-minute intelligence brief
Recalls, FDA clearances & safety signals as they hit

See everything you get →

Cancel anytime, one click · 14-day money-back on annual

Discussion

Inside MedSpa Pro

By the time it's news, it's too late.

The rebate cut, the scope-of-practice bill, the competitor opening down the street — it hits your business before the trade press ever covers it. Pro gets you there first: what happened, why it touches your margins, and exactly what to do — at 6 AM, in two minutes.

Go Pro · $20/mo Never miss a recall or a rule change. Cancel anytime.

The twice-a-week intelligence brief Go Pro · $20/mo →

What Is Your Medspa Worth? Valuation & EBITDA Multiples

Discussion

Leave a comment

By the time it's news, it's too late.